Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
+0.67 (2.41%)
Mar 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 27.85 - 28.59
52 week 19.31 - 30.96
Open 27.85
Vol / Avg. 152,343.00/307,016.00
Mkt cap 1.08B
P/E 58.92
Div/yield     -
EPS 0.48
Shares 37.92M
Beta 1.09
Inst. own 80%
May 22, 2015
Emergent BioSolutions Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 6, 2015
Q1 2015 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 26, 2015
Emergent BioSolutions Inc at Maidstone Life Sciences Cancer Immunotherapy: A Long-Awaited Reality Conference
Mar 10, 2015
Emergent BioSolutions Inc at Credit Suisse Under Followed Opportunities Conference
Mar 5, 2015
Q4 2014 Emergent BioSolutions Inc Earnings Call - Webcast
Mar 5, 2015
Q4 2014 Emergent BioSolutions Inc Earnings Release
Mar 2, 2015
Emergent BioSolutions Inc at Cowen Health Care Conference
Jan 20, 2015
Emergent BioSolutions Inc at Noble Financial Equity Conference
Jan 12, 2015
Emergent BioSolutions Inc at JPMorgan Healthcare Conference
Jan 11, 2015
Preliminary 2014 Emergent BioSolutions Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 20.35% 8.16%
Operating margin 30.15% 12.90%
EBITD margin - 20.11%
Return on average assets 13.31% 4.67%
Return on average equity 22.66% 7.05%
Employees 1,280 -
CDP Score - -


400 Professional Dr Ste 400
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense division and BioSciences division. The BioDefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or bio-warfare and targets the infectious disease, anthrax. Its programs include a pipeline of investigational product candidates and one marketed product, BioThrax (Anthrax Vaccine Adsorbed). The Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. Its products include WinRho SDF, HepaGam B, VARIZIG and Episil.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Age: 56
Bio & Compensation  - Reuters
Anatolio B. Cruz III Executive Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Adam Havey Executive Vice President, President - BioDefense Division
Age: 43
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 50
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 58
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 60
Bio & Compensation  - Reuters